Scholars Central

Mini reviewPublished 19 Mar 2024

One Significant Advancement for Thyroid Eye Disease, One Incremental Step Forward for Doxycycline

Authors: Ines Vatavuk

Reports in Thyroid Research

Volume 8 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Thyroid eye disease, also known as Graves' orbitopathy, is an autoimmune condition characterized by inflammation and swelling of the tissues around the eyes. The disease can cause significant morbidity and affect the quality of life of affected individuals. In recent years, several advancements have been made in the management of TED, including the development of new treatment modalities and the repurposing of existing medications. This article reviews one significant advancement in the treatment of TED, the use of teprotumumab, and one incremental step forward in the use of doxycycline, an existing medication with potential benefits in TED management. The treatment landscape for Thyroid Eye Disease has evolved significantly, with advancements like Teprotumumab offering new hope for patients. This biologic has set a new standard for efficacy in reducing proptosis and improving eye function in TED patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalReports in Thyroid Research
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Ines Vatavuk”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels